Alexander Mustea
University Hospital, Bonn
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alexander Mustea as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:39 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02203760 · Pazopanib Vs. Pazopanib Plus GemcitabineNorth Eastern German Society of Gynaecological Oncology · active not recruiting · Leiomyosarcoma or Carcinosarcoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:39 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.N Engl J Med · 2019435 citationsRCR 18.6
- Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB-IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study.Int J Gynecol Cancer · 202098 citationsRCR 5.8
- Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective randomized trial.Am J Obstet Gynecol · 201546 citationsRCR 1.9
- Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.Cancer Chemother Pharmacol · 200831 citationsRCR 0.7
- Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology).Cancer Chemother Pharmacol · 201315 citationsRCR 0.4
- 15 citationsRCR 1.1
- Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.Cancer Chemother Pharmacol · 200813 citationsRCR 0.3
- Clinical Outcome of Neoadjuvant Radiochemotherapy in Locally Advanced Cervical Cancer: Results of an Open Prospective, Multicenter Phase 2 Study of the North-Eastern German Society of Gynecological Oncology.Int J Gynecol Cancer · 201713 citationsRCR 0.5
- 9 citationsRCR 2.9
- Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study.Support Care Cancer · 20106 citationsRCR 0.2